公司資料
Dr. Reddy's Laboratories Ltd 股價、新聞與催化劑
- 股票代碼:
- RDY
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- India and listed in the U
股票表現
12.25 USD (-2.93%)
收盤價
最後更新: 2026年10月1日
10.8B USD
市值
股價為何變動
截至 2026年10月1日，RDY 下跌 2.93%，收於 $12.25。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
India-Based Global Pharmaceutical Company
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in India. Its businesses include generic medicines, branded formulations, biosimilars, active pharmaceutical ingredients, pharmaceutical services, consumer health products, and selected innovative drug-development programs.
Global Generics Business
The Global Generics segment operates across North America, Europe, India, and emerging markets. It supplies oral solids, injectables, dermatology products, complex generics, and branded generics, with local commercial organizations adapting the portfolio to each market's regulatory and prescribing structure.
Branded and Consumer Health Portfolio
India and emerging markets contain substantial branded-prescription businesses, while acquired nicotine-replacement products have expanded the company's consumer-health presence. These businesses provide a different commercial model from the more price-sensitive U.S. generics market.
Pharmaceutical Services and APIs
The Pharmaceutical Services and Active Ingredients segment develops and manufactures active pharmaceutical ingredients and provides related capabilities to external customers. Vertical integration also supports selected finished-dose products and gives Dr. Reddy's experience in complex chemistry and global quality systems.
Peptides, Biosimilars, and Innovative Assets
The growth pipeline emphasizes peptides, biosimilars, and differentiated products. Programs involving semaglutide, abatacept, and other complex molecules are intended to move the company beyond conventional small-molecule generics while leveraging its development and manufacturing scale.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。